NeoGenomics (NEO) Tops Q1 EPS by 10c; Guides for FY16 Adjusted Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains
April 27, 2016 7:00 AM EDTFT. MYERS, Fla., April 27, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2016.
First Quarter 2016 Highlights:
159% increase in consolidated revenue to a record $59.7 million 442% increase in consolidated Adjusted EBITDA(1) to record $8.2 million 175% increase in consolidated clinical genetic testing volume(2) Adjusted Diluted EPS(1) of $0.03 per share and Diluted EPS of ($0.07) per shareConsolidated Revenue for the fourth quarter was $59.7... More
